Table 3 Immunohistochemical expression of PD-L1 in all study cases
Tumor groups | Group A | Group B | Group C | Groups A–C | Group D | Group E | Groups A–E | p value (1)* | p value (2)** |
|---|---|---|---|---|---|---|---|---|---|
MMRd-LS | MMRd-unexplained | MMRd-sporadic | MMRd total | MMRp-TIL-H | MMRp-consecutive | Grand total | |||
# of tumors | 23 | 13 | 37 | 73 | 17 | 39 | 129 | ||
PD-L1 IHC | |||||||||
≥5% TSI_overall | 21 (91%) | 13 (100%) | 31 (84%) | 65 (89%) | 13 (76%) | 12 (31%) | 90 (70%) | 0.2296 | <0.0001 |
≥30% TSI_overall | 17 (74%) | 10 (77%) | 24 (65%) | 51 (70%) | 11 (65%) | 2 (5%) | 64 (50%) | 1 | <0.0001 |
≥30% TSI_IC | 15 (65%) | 8 (62%) | 12 (32%) | 35 (48%) | 10 (59%) | 2 (5%) | 47 (36%) | 0.2924 | <0.0001 |
≥30% TSI_AC | 2 (9%) | 2 (15%) | 10 (27%) | 14 (19%) | 0 | 0 | 14 (11%) | 0.0647 | 0.0011 |
≥30% TSI_TC | 0 | 0 | 2 (5%) | 2 (3%) | 1 (6%) | 0 | 3 (2%) | 0.4706 | 0.542 |
PD-L1 + SATB2 IHC | |||||||||
True tumor cell staining | 0 | 0 | 2 (5%) | 2 (3%) | 1 (6%) | 0 | 3 (2%) | 0.4706 | 0.542 |
